Protect Your Patient’s Arterial Line with BIOPATCH® PROTECTIVE DISK with CHG

High Incidence
- There are approximately 48,000 arterial Catheter Related Bloodstream Infections (CRBSI) annually.\(^1\)
- Arterial catheters are used in more than 6 million patients in US hospitals each year.\(^2\)

The Risks
- Arterial catheters are among the most heavily manipulated catheters in the ICU and the OR, as a result, the risk of arterial CRBSI is close to that seen with short-term noncuffed Central Venous Catheters (CVCs).\(^2\)
- According to the CDC, Arterial Lines and CVCs have similar risk of CRBSI\(^3\)

**Rates of CRBSI Per 1,000 Catheter Days\(^2\)**

<table>
<thead>
<tr>
<th>Catheter Type (# of Studies)</th>
<th>Number of Patients</th>
<th>Number of Arterial Lines</th>
<th>Number of Venous Lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIV (110)</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICC (15)</td>
<td>1.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dialysis cuffed (16)</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVC non-cuffed/CHG-SS Coated (18)</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial (14)</td>
<td>1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVC non-cuffed/non-medicated (79)</td>
<td>2.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dialysis non-cuffed (16)</td>
<td>4.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

“Since almost all the national effort and progress to date to reduce the risk of IVD-related infection have focused on short-term noncuffed CVCs used in intensive care units, infection control programs must now strive to consistently apply essential control measures and preventive technologies with all types of IVDs.”\(^2\)

– Maki / Kluger, 2006

**BIOPATCH Disk - Clinically Proven to Reduce Arterial Line Infections**
In two of the largest Randomized Clinical Trials proving BIOPATCH Disk’s efficacy in reducing CRBSIs, arterial lines were included in the study group.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Meeting/Journal</th>
<th>Number of Patients</th>
<th>Number of Arterial Lines</th>
<th>Number of Venous Lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timsit</td>
<td>2009</td>
<td>Journal of the American Medical Association</td>
<td>1,636</td>
<td>1,727</td>
<td>2,051</td>
</tr>
<tr>
<td>Maki</td>
<td>2000</td>
<td>Fortieth Interscience Conference of Antimicrobial Agents and Chemotherapy</td>
<td>589</td>
<td>613</td>
<td>785</td>
</tr>
</tbody>
</table>
WARNING: Not for use on premature infants or patients with known sensitivity to CHG. Safety and effectiveness in children under 16 years of age has not been established.

References
5. Infusion Therapy Standards of Practice, Journal of Infusion Nursing. 2016, V39 (1S)
8. BIOPATCH Disk has been proven to reduce CRBSIs by 60% in patients with central venous and arterial catheters.

BIOPATCH® Protective Disk with CHG – the Evidence-based Choice.

BIOPATCH Disk has been proven to reduce CRBSIs by 60% in patients with central venous and arterial catheters.

INDICATION FOR USE

BIOPATCH® Protective Disk with CHG is intended for use as a hydrophilic wound dressing that is used to absorb exudate and to cover a wound caused by the use of vascular and non-vascular percutaneous medical devices such as: IV catheters, central venous lines, arterial catheters, dialysis catheters, peripherally inserted coronary catheters, mid-line catheter, drains, chest tubes, externally placed orthopedic pins, and epidural catheters. It is also intended to reduce local infections, catheter-related bloodstream infections (CRBSI), and skin colonization of microorganisms commonly related to CRBSI, in patients with central venous or arterial catheters.

For Full Prescribing Information or technical support, call 1-877-ETHICON (1-877-384-4266) or visit www.biopatch.com.

To place an order, call 1-800-255-2500.

*WARNING: Not for use on premature infants or patients with known sensitivity to CHG. Safety and effectiveness in children under 16 years of age has not been established.

References